Arvinas, Inc. (ARVN) Financial Ratios
10 years of historical data (2016–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: 7.40
30Y Low7.4·High7.4
P/B Ratio
↓
1.53
↓-53% vs avg
5yr avg: 3.23
30Y Low1.8·High6.0
ROE
↑
-16.2%
↓+54% vs avg
5yr avg: -35.5%
30Y Low-198%·High-16%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ARVN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Arvinas, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $656M | $770M | $1.4B | $2.3B | $1.8B | $4.1B | $3.4B | $1.4B | $406M | — | — |
| Enterprise Value | $522M | $635M | $1.3B | $2.0B | $1.7B | $4.0B | $2.8B | $1.3B | $405M | — | — |
| P/E Ratio → | -8.02 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 2.50 | 2.93 | 5.23 | 29.10 | 13.85 | 76.62 | 129.64 | 31.48 | 28.37 | — | — |
| P/B Ratio | 1.53 | 1.77 | 2.45 | 3.46 | 3.22 | 5.25 | 5.23 | 5.97 | 2.97 | — | — |
| P/FCF | — | — | — | — | — | 7.40 | — | — | — | — | — |
| P/OCF | — | — | — | — | — | 7.34 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ARVN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.42 | 4.89 | 25.17 | 13.27 | 74.70 | 107.08 | 31.37 | 28.30 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | 7.22 | — | — | — | — | — |
ARVN Profitability
Margins and return-on-capital ratios measuring operating efficiency
Arvinas, Inc. earns an operating margin of -43.8%. Operating margins have expanded from -511.5% to -43.8% over the past 3 years, signaling improving operational efficiency. A negative ROE of -16.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 98.0% | 98.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -43.8% | -43.8% | -95.0% | -511.5% | -200.3% | -351.5% | -466.4% | -119.9% | -305.8% | -326.7% | -247.0% |
| Net Profit Margin | -30.8% | -30.8% | -75.5% | -467.9% | -215.0% | -356.3% | -460.6% | -163.6% | -289.6% | -317.3% | -215.2% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -16.2% | -16.2% | -32.6% | -60.0% | -42.0% | -26.8% | -27.5% | -38.7% | -60.6% | -198.1% | -59.7% |
| ROA | -8.9% | -8.9% | -16.6% | -28.5% | -19.8% | -16.6% | -23.4% | -28.1% | -31.2% | -45.9% | -37.8% |
| ROIC | -22.4% | -22.4% | -45.6% | -71.6% | -33.8% | -38.4% | -64.8% | -21.6% | -62.4% | — | -63.7% |
| ROCE | -16.0% | -16.0% | -26.2% | -39.7% | -23.0% | -19.0% | -25.8% | -23.2% | -38.9% | -64.4% | -59.0% |
ARVN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $143M exceeds total debt of $9M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.00 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 1.26 | 0.02 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.31 | -0.16 | -0.47 | -0.13 | -0.13 | -0.91 | -0.02 | -0.01 | -124.46 | -0.19 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | -0.19 | — | — | — | -7.46 | — |
| Interest Coverage | — | — | — | — | — | -1884.00 | -1858.46 | -702.07 | -721.15 | -476.57 | -213.20 |
Net cash position: cash ($143M) exceeds total debt ($9M)
ARVN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Arvinas, Inc.'s current ratio of 4.92x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 4.98x to 4.92x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.92 | 4.92 | 4.64 | 4.98 | 4.20 | 5.93 | 14.29 | 8.86 | 8.52 | 3.67 | 3.72 |
| Quick Ratio | 4.92 | 4.92 | 4.64 | 4.98 | 4.20 | 5.93 | 14.29 | 8.86 | 8.52 | 3.67 | 3.72 |
| Cash Ratio | 4.81 | 4.81 | 4.52 | 4.90 | 4.08 | 5.74 | 14.00 | 8.56 | 8.17 | 2.19 | 3.54 |
| Asset Turnover | — | 0.37 | 0.24 | 0.06 | 0.10 | 0.03 | 0.04 | 0.14 | 0.07 | 0.11 | 0.18 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 8.90 | 18.98 | 33.48 | 22.22 | 175.01 | 118.38 | 53.34 | 128.22 | 1254.11 | 77.18 |
ARVN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Arvinas, Inc. returns 14.0% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | 13.5% | — | — | — | — | — |
| Buyback Yield | 14.0% | 11.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 14.0% | 11.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $65M | $72M | $56M | $53M | $50M | $40M | $33M | $32M | $21M | $2M |
Peer Comparison
Compare ARVN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ARVNYou | $656M | -8.0 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 KYMR | $7B | -23.4 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 PRAX | $8B | -25.1 | — | — | — | — | -45.8% | -65.0% | — |
 MDGL | $12B | -42.0 | — | — | 94.1% | -31.3% | -42.5% | -38.2% | — |
 PTCT | $6B | 8.6 | 5.6 | 7.9 | 95.9% | 49.5% | — | — | 0.5 |
 RCUS | $3B | -7.9 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 RVMD | $30B | -25.4 | — | — | — | — | -58.1% | -54.3% | — |
 PFE | $151B | 19.5 | 10.7 | 16.6 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 BMY | $115B | 16.4 | 9.2 | 9.0 | 67.6% | 26.3% | 40.4% | 16.9% | 2.8 |
 CRL | $9B | -62.5 | 13.0 | 17.3 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
 IQV | $30B | 22.5 | 12.9 | 14.6 | 26.3% | 14.0% | 21.4% | 8.7% | 4.7 |
| Healthcare Median | — | 22.2 | 14.1 | 18.6 | 64.1% | -5.3% | -34.0% | -11.2% | 3.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 10 years · Updated daily
See ARVN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARVN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ARVN vs KYMR
Side-by-side business, growth, and profitability comparison vs Kymera Therapeutics, Inc..
Start ComparisonARVN — Frequently Asked Questions
Quick answers to the most common questions about buying ARVN stock.
What is Arvinas, Inc.'s P/E ratio?
Arvinas, Inc.'s current P/E ratio is -8.0x. This places it at the 50th percentile of its historical range.
What is Arvinas, Inc.'s ROE?
Arvinas, Inc.'s return on equity (ROE) is -16.2%. The historical average is -56.2%.
Is ARVN stock overvalued?
Based on historical data, Arvinas, Inc. is trading at a P/E of -8.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Arvinas, Inc.'s profit margins?
Arvinas, Inc. has 98.0% gross margin and -43.8% operating margin.